Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis

od Debled, M, Houédé, N, Madranges, N, Donamaria, C, Floquet, A, Durand, M, Mauriac, Louis
Izdano 2007

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO

od Ray-Coquard, I, Favier, L, Weber, B, Roemer-Becuwe, C, Bougnoux, P, Fabbro, M, Floquet, A, Joly, F, Plantade, A, Paraiso, D, Pujade-Lauraine, E
Izdano 2013

DNA topoisomerase IIα expression and the response toprimary chemotherapy in breast cancer

od MacGrogan, G, Rudolph, P, Mascarel, I de, Mauriac, L, Durand, M, Avril, A, Dilhuydy, J M, Robert, J, Mathoulin-Pélissier, S, Picot, V, Floquet, A, Sierankowski, G, Coindre, J M
Izdano 2003

Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group

od Heudel, P-E, Fabbro, M, Roemer-Becuwe, C, Kaminsky, M C, Arnaud, A, Joly, F, Roche-Forestier, S, Meunier, J, Foa, C, You, B, Priou, F, Tazi, Y, Floquet, A, Selle, F, Berton-Rigaud, D, Lesoin, A, Kalbacher, E, Lortholary, A, Favier, L, Treilleux, I, Ray-Coquard, I
izdano v Br J Cancer (2017)